BioMedPartners
Venture capitalBasel · Seed–Late Stage · 6 people tracked
Team · 6 people
from the firm's websiteFrequently asked questions
- What stage does BioMedPartners invest at?
- BioMedPartners invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What is BioMedPartners's typical check size?
- BioMedPartners typically writes checks of $648K – $6.5M.
- What sectors does BioMedPartners focus on?
- BioMedPartners focuses on Biotech, Medical Devices.
- Where is BioMedPartners located?
- BioMedPartners is headquartered in Basel, CH.
Similar investors
3TS Capital is a technology investment firm with over 25 years of experience managing multiple fund generations. The firm partners with exceptional founders to scale internationally, targeting high-growth SMEs that are either proven local leaders or innovative global challengers.
500 Global's Sustainable Growth practice designs and implements sovereign-aligned strategies that unlock resilient, inclusive, and sustainable economic growth across the Global Majority—Asia, Africa, Latin America, and the Middle East. The practice bridges public priorities and private capital through ecosystem development, blended finance, and localized innovation programs addressing health, agriculture, gender, climate, and education.
83North is a lean venture capital partnership of four equal general partners that has operated for 19 years. The firm invests globally across the US, Europe, and Israel, and in 2025 raised what it describes as its final fund, shifting focus toward selectively pursuing new opportunities while supporting existing portfolio companies.
8VC is a technology investment firm focused on building and investing in ambitious companies across life sciences, healthcare, manufacturing, enterprise, logistics, and defense sectors, with particular emphasis on operational intelligence and data-driven decision-making.